were full-time employees of Pfizer during the conduct of this study.
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Conclusions:
The clinical activity demonstrated in this study points to PF-03446962 as a novel approach to antiangiogenic therapy, with manageable safety profile and singleagent, antitumor activity in patients with advanced solid tumors.
TRANSLATIONAL RELEVANCE
ALK-1 is a serine/threonine kinase receptor involved in vessel maturation during embryogenesis and tumor neovascularization. PF-03446962, a first-in-class, fully human anti-ALK-1 monoclonal antibody, selectively blocks binding of the ALK-1 ligands bone morphogenetic protein-9 and TGF-β, and inhibits recruitment of the co-receptor endoglin. PF-03446962 has demonstrated anti-angiogenic activity in human xenograft tumor models. In this first-in-human study, treatment with single-agent PF-03446962 was generally well tolerated; the maximum tolerated dose was estimated to be 10 mg/kg and the recommended phase II dose set at 7 mg/kg. The pharmacokinetic profile observed supports biweekly administration of PF-03446962. Treatment was associated with a manageable safety profile and preliminary evidence of clinical activity. A substantial reduction in tumor perfusion was observed by contrast-enhanced ultrasound in 2 patients with actively perfused tumors at baseline who achieved stable disease following treatment. ALK-1 inhibition by PF-03446962 represents an intriguing new strategy for antiangiogenic therapy in patients with solid malignancies.
Introduction
Transforming growth factor-beta (TGF-β) regulates multiple biological processes associated with tumor development and progression (1) . TGF-β signals through the ubiquitously expressed type I activin-receptor like kinase (ALK)-5 and the more restricted receptors ALK-1 and endoglin (2) . ALK-1 is a serine/threonine kinase receptor, preferentially expressed on proliferating endothelial cells, which binds with high affinity the bone morphogenetic protein (BMP) 9 and 10, both members of the TGF-β ligand super family (3) (4) (5) . Endoglin is a type III TGF-β receptor required for vascular development, upregulated by endothelial cell activation in inflammation and tumor-associated angiogenesis (2) . PF-03446962 is a first-in-class, fully human anti-ALK-1 monoclonal antibody (immunoglobulin G2). It has been shown in preclinical studies to selectively block binding of the ALK-1 ligands BMP-9 and TGF-β to ALK-1, and to inhibit recruitment of the co-receptor endoglin into the ALK-1 angiogenesis-signaling complex (10) (11) (12) . PF-03446962 demonstrated antiangiogenic activity in human xenograft tumor models (12) .
It inhibited ALK-1 signaling and endothelial cell sprouting induced by proangiogenic factors, but did not affect VEGF signaling and VEGF-induced proliferation or migration of endothelial cells, thus providing evidence of a novel mechanism to inhibit angiogenesis (11) .
Objectives of this first-in-human study were to estimate the maximum tolerated dose (MTD), define the recommended phase II dose (RP2D), and characterize the safety profile, pharmacokinetics (PK), and antitumor activity of PF-03446962 in patients with advanced solid tumors.
Patients and Methods
Study design and patient selection
This multicenter, open-label, single-arm, dose-finding, phase I study was conducted in patients with treatment-refractory solid tumors or with no available standard treatment, using a standard 3+3 design. Primary endpoints were to estimate the MTD and determine the RP2D for biweekly treatment with PF-03446962. Secondary endpoints included evaluation of the safety, PK profile, and immunogenicity of PF-03446962, and preliminary assessment of its antitumor activity.
Research. Patients with histologically or cytologically confirmed, treatment-refractory solid tumors, or advanced disease and either intolerance to or no available standard therapy were included in the study. Patients had to have Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1; a life expectancy ≥12 weeks; and adequate bone marrow (absolute neutrophil count ≥1500/μL; platelets ≥100,000/μL, hemoglobin ≥9 g/dL), renal, and hepatic function. Eligible patients were enrolled in the dose escalation portion of this study at 3 sites, 2 in the United States and 1 in Italy.
Patients were excluded from the study if they had an active bleeding disorder, experienced cardiovascular events within 12 months of study entry, had a QT interval corrected for heart rate > 470 msec, uncontrolled hypertension, or active brain metastases. Patients with a history of HHT were excluded from this study. In addition, patients were not included if they required anticoagulant therapy (with the exception of low-dose, prophylactic anticoagulants) or had received chemotherapy, radiation therapy, or any investigational anticancer therapy within 4 weeks of study drug initiation. observed-adverse-effect level of 50 mg/kg in a repeat-dose toxicity study conducted in monkeys and adding a 100-fold additional safety factor. The dose level was escalated by 100% increments until a non-disease-related grade 2 or greater AE occurred in ≥1 patient within the same cohort or if 1 in 6 patients in the same cohort experienced a dose-limiting toxicity (DLT). Thereafter, dose escalation was continued in 50% increments until 2 of 3 or 2 of 6 patients experienced a DLT. Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.
DLT was defined as any grade 3 or greater hematologic or non-hematologic AE occurring during the first 6 weeks possibly related to treatment with PF-03446962. 
Assessments
Safety
Antitumor activity
Objective tumor assessments were performed by computed tomography or magnetic resonance imaging at screening, 6 weeks after the first dose of PF-03446962, and approximately every 6 weeks thereafter, according to Response Evaluation Criteria in Solid Tumors, version 1.0. Endpoints included complete or partial response and stable disease, which were confirmed by tumor imaging.
Tumor vascular activity
Three consecutive patients were examined with contrast-enhanced ultrasound (CE-US) to evaluate its feasibility in assessing early tumor response to treatment. All 3 patients had liver lesions accessible to routine gray-scale ultrasound imaging. CE-US scans were obtained for each patient at baseline (2 scan sets/patient to determine variability) and on days 1 and 15 post first dose. Sonography and image analysis were performed with an iU22 scanner and Q-Lab software, respectively (Philips Medical Systems, Bothell, WA). Additional details are described online in Supplementary Methods.
Statistical analyses
The number of patients to be enrolled at each dose level and the number of dose cohorts were dependent on the safety profile observed during the course of the study.
Descriptive statistics were used throughout the study. A 90% exact confidence interval was calculated for the response rate. 
Results
Patients
A total of 44 patients were enrolled and treated at doses ranging from 0.5 to 15 mg/kg:
Patient cohort enrollment, demographics, and disease characteristics are presented in Table 1 . Twelve of the 44 patients on study had colorectal cancer; 5 each had liver, renal/adrenal, or lung cancer; and 4 each had other gastrointestinal cancers (pseudomyxoma peritonei, gastrointestinal stromal tumor, and esophageal squamous cell carcinoma) or thyroid cancer. Patients with pancreatic (n = 3), gynecologic (n = 2), or prostate (n=1) cancer, sarcoma (n = 2), or malignant thymoma (n = 1) were also enrolled in this trial.
Ninety-six percent of patients had stage IV disease at the time of diagnosis; the majority (66%) had ECOG PS 1. All patients had received prior systemic, anticancer treatment, and 71% had been treated with 3 or more regimens.
DLT and safety
All patients received ≥1 dose of study drug and were thus evaluable for DLTs, which included DLTs observed in cycles 1 and 2, and during follow-up if the AE occurred after cycle 2, up to day 1 of cycle 3. DLTs included grade 3 increased amylase and lipase in All treated patients reported a treatment-emergent, all-cause AE across dose levels, of which the most frequent (% patients) were fatigue (29.5%), nausea (29.5%) and thrombocytopenia (22.7%) ( Table 3) . Twenty-nine (65.9%) patients experienced a treatment-related AE. The most frequent (% patients) treatment-related AEs included thrombocytopenia (20.5%), fatigue (15.9%), and nausea, increased amylase, and increased lipase (all 11.4%) ( Table 3) . In almost all patients, a reduction in platelets ("trough") was observed in cycle 1 between days 8 and 15, with a trend to recovery. The occurrence of thrombocytopenia was not associated with bleeding. The observed elevations in pancreatic enzymes were limited to laboratory alterations and were transient in nature. Skin telangiectasia was reported in 4 (9.1%) patients and deemed related to study treatment in 3 (6.8%) patients. Examples of telangiectasia observed in patients treated with PF-03446962 are shown in Supplementary Fig. S1 .
Nineteen (43.2%) patients experienced grade 3-4 AEs, which were considered treatment-related in 8 (18.2%) patients. In the 6.75-mg/kg group, later identified as the RP2D, 1 patient experienced grade 4 treatment-related thrombocytopenia and 1 patient each had a grade 3 treatment-related pulmonary embolism, increased alanine aminotransferase, and increased aspartate aminotransferase.
None of the 3 deaths reported (2 at 6.75-mg/kg and 1 at 15-mg/kg doses) were considered to be treatment-related. They were due to disease progression in 1 patient each with renal cell carcinoma, non-small-cell lung cancer, and adenocarcinoma of the pancreas.
Two (4.5%) patients had a dose reduction owing to AEs (treatment-related in 1 patient) and 15 (34.1%) had temporary discontinuations due to AEs (treatment-related Table S2 ). Twelve (27.3%) patients had stable disease across dose levels (0.5-to 15-mg/kg), which lasted >16 weeks in 6 patients (Fig. 1B) .
In the 2-mg/kg group, the patient with a partial response had a primary diagnosis of 
CE-US analysis
Research.
on
Three patients with colon cancer metastatic to the liver completed CE-US examinations; all had good reproducibility at baseline. All 3 patients had received prior therapy with bevacizumab and treatment had been discontinued for disease progression, completed treatment, or unknown reason (1 patient each). Two of the 3 patients (with SD for 21 and 165 days, respectively) demonstrated well-perfused target liver lesions on pretreatment imaging, as characterized by high peak CE (25dB, 15 dB), microvascular density (22.7 dB, 21.5 dB), and blood-flow velocity (1.1 1/sec, 0.52 1/sec). The third patient, with progressive disease 35 days after PF-03446962 treatment initiation and prior bevacizumab failure, had a target lesion with decreased perfusion on the pretreatment scan, compared with patients with stable disease, with relatively low peak CE (8.9dB), low microvascular density (1.9 dB), and slow blood-flow velocity (0.04 1/sec).
Both patients with stable disease showed a substantial reduction in lesion perfusion on day 15 post first dose. Peak CE had decreased by 32% (to 17 dB) and 33% (to 10 dB), respectively; microvascular density by 40% (to 13.7 dB) and 56% (to 9.4 dB); and blood-flow velocity by 36% (to 0.7 1/sec) and 35% (to 0.34 1/sec) (Fig. 3) . In contrast, the patient with progressive disease showed an increase in CE-US parameters of tumor perfusion on day 15. Peak CE had increased by 27% (to 11.3 dB), microvascular density by 68% (to 3.2 dB), and blood-flow velocity had increased fourfold (to 0.2 1/sec).
None of the patients demonstrated measurable (>5%) change in tumor size.
Discussion
We report findings from the first-in-human study of the anti-ALK-1 monoclonal antibody PF-03446962 in patients with advanced solid tumors. PF-03446962 was generally well Although the MTD was 10 mg/kg biweekly, the RP2D for PF-03446962 was determined to be 7 mg/kg biweekly, based on the safety, tolerability, and PK results, as well as the antitumor activity observed in this study. In addition, the half-life at this dose level was ~10 days and the concentrations observed well exceeded the efficacious concentration [EC 50 ] derived from preclinical studies following a PF-03446962 dose of 7 mg/kg biweekly. Of note, the dose of 7 mg/kg biweekly was selected as the RP2D to be used in future studies to prevent possible effects on platelets in a potentially fragile population, such as patients with hepatocellular carcinoma, which was the clinical setting chosen for further development of this investigational agent. Preliminary analysis of the results obtained from evaluation of PF-03446962 in an expansion cohort of patients with hepatocellular carcinoma confirmed 7 mg/kg biweekly as the RP2D for the treatment of patients with advanced solid tumors (18, 19) . Dosing of therapeutic monoclonal antibodies was generally based on body size, with the consideration that body size-based dosing would reduce intersubject variability in drug exposure. However, recent studies suggest that body size has a small contribution to variability in key PK parameters of most monoclonal antibodies, on the basis of population pharmacokinetic models (20) . Therefore, our dosing strategy in clinical development will further assess fixed dosing, which provides many practical advantages, based on combined knowledge of the body weight effect on PK, safety, and efficacy from early clinical studies with PF-03446962.
The preliminary CE-US results are encouraging and indicate that pre-treatment CE-US has the potential to become a useful tool to select patients with vascular tumors potentially more responsive to treatment than hypovascular ones. In addition, CE-US 
has a substantial potential to serve as a non-invasive tool to predict antiangiogenic tumor response as early as 15 days after treatment initiation. In the small group tested 
